|
Summary
February 2008, Vol. 9, No. 3, Pages 479-490
, DOI 10.1517/14656566.9.3.479
Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectivesLeonardo Michele Fabbri1University of Modena & Reggio Emilia, Department of Respiratory Diseases, Via del Pozzo 71, I-41100 Modena, Italy +39 0594222198; +39 0594224231; fabbri.leonardo@unimore.it 2Medical Department, Chiesi Farmaceutici, Parma, Italy 3University of Parma, Cardio-Pulmonary Department, Section of Respiratory Diseases, Italy 4University of Ferrara, Research Center on Asthma and COPD, Ferrara, Italy †  Author for correspondenceBackground: Combinations of a long-acting β2-agonist (LABA) and an inhaled corticosteroid (ICS) are effective and safe options in asthma management. Objective: To review available data on a recently developed combination of beclometasone dipropionate (BDP) and formoterol (F) given via a pressurized metered-dose inhaler. Methods: Published data on preclinical and clinical studies were reviewed. Results/conclusion: In the treatment of asthma, BDP/F was shown to be at least as effective and well-tolerated as other available combinations of ICS and LABA with the advantage of a better cost effectiveness, and more effective in improving asthma control than BDP and formoterol given via separate inhalers. The extra-fine BDP/F combination appears to be a valuable therapeutic option in the management of asthma. Users who read this article also read:
|
|
TOC Alert